Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR1A | P08908 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8916932 | 0.87 | SIGMAR1 (0.59) | KCNH2SIGMAR1L3MBTL1MIF | |
| SCHEMBL1270016 | 0.85 | SIGMAR1 (0.59) | SIGMAR1L3MBTL1MIF | |
| SCHEMBL11103198 | 0.84 | SIGMAR1 (0.62) | SIGMAR1L3MBTL1MIF | |
| SCHEMBL11107579 | 0.84 | SIGMAR1 (0.62) | SIGMAR1L3MBTL1MIF | |
| SCHEMBL2243709 | 0.77 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL7631772 | 0.77 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL349780 | 0.77 | ALDH1A1 (0.52) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL2549267 | 0.76 | ALOX12 (0.48) | IDO1MAOAALDH1A1CYP3A4GAA | |
| SCHEMBL4253869 | 0.74 | ATM (0.54) | NPC1RAB9ASMN1; SMN2TAAR1LMNA | |
| SCHEMBL10754359 | 0.73 | ALDH1A1 (0.58) | NPC1RAB9ASMN1; SMN2TAAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 631 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3632441-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE COMPOUND | DAY ONE BIOPHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-118344346-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-16 | — | — | CN | disclosed |
| EP-3782986-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-10 | — | — | EP | disclosed |
| CN-118290408-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-05 | — | — | CN | disclosed |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-04 | — | — | US | disclosed |
| CN-118271298-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-07-02 | — | — | US | disclosed |
| CN-118271297-A | Heterocyclic compounds and their use | 武田药品工业株式会社 | 2024-07-02 | — | — | CN | disclosed |
| US-12012419-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-18 | — | — | US | disclosed |
| WO-2024116086-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-06-06 | — | — | WO | disclosed |
| CN-101356161-A | Heterocyclic CETP inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2009-01-28 | — | — | CN | disclosed |
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | BIOLIPOX AB (SE) | 2008-04-17 | — | — | US | disclosed |
| US-6331548-B1 | PREVENTION OR TREATMENT OF CYTOKINE RELATED DISEASES | SUNTORY LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-0978516-A1 | 1-CYCLOALKYL-1,8-NAPHTHYRIDIN-4-ONE DERIVATIVES WITH PHOSPHODIESTERASE IV INHIBITORY ACTIVITY | SUNTORY LIMITED (JP) | 2000-02-09 | — | — | EP | disclosed |
| US-5616581-A | BACTERICIDES | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1997-04-01 | — | — | US | disclosed |
| US-5504082-A | BACTERICIDE FOR HELICOBACTER, ANTIULCER AGENT, GASTRIC ACIDSUPPRESSOR | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0644191-A1 | PYRIDINE COMPOUND AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-4933355-A | ALDOSE REDUCTASE INHIBITORS | SANKYO COMPANY LIMITED (JP) | 1990-06-12 | — | — | US | disclosed |
| EP-0337819-A1 | Thiazole derivatives, their preparation and their use in the treatment of diabetes complications | Sankyo Company Limited (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0104432-A2 | Herbicide and plant growth regulator comprising alpha-beta-unsaturated compound | TEIJIN LIMITED (JP) | 1984-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090836-A1 | Pyrazole Compounds Useful In The Treatment Of Inflammation | ALOX15, ALOX15B, ALOX12 | NPC1 4200/4885RAB9A 1958/4885SMN1; SMN2 4380/4885 |
| US-20240217957-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | HCRTR2, HCRTR1, NPY2R | NPC1 535/4885RAB9A 2554/4885SMN1; SMN2 1350/4885 |
| US-12024505-B2 | Heterocyclic compounds useful as modulators of acetylcholine receptors | CHRM3, CHRNA1, CHRM5 | NPC1 1832/4885RAB9A 1052/4885SMN1; SMN2 2791/4885 |
| US-12012419-B2 | Heterocyclic compound | SLC10A2, ALPI, SLC10A1 | NPC1 875/4885RAB9A 1771/4885SMN1; SMN2 879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.